These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

419 related items for PubMed ID: 20107315

  • 1. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil.
    Hirai H, Arai T, Okada M, Nishibata T, Kobayashi M, Sakai N, Imagaki K, Ohtani J, Sakai T, Yoshizumi T, Mizuarai S, Iwasawa Y, Kotani H.
    Cancer Biol Ther; 2010 Apr 01; 9(7):514-22. PubMed ID: 20107315
    [Abstract] [Full Text] [Related]

  • 2. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents.
    Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M, Kimura T, Kaneko N, Ohtani J, Yamanaka K, Itadani H, Takahashi-Suzuki I, Fukasawa K, Oki H, Nambu T, Jiang J, Sakai T, Arakawa H, Sakamoto T, Sagara T, Yoshizumi T, Mizuarai S, Kotani H.
    Mol Cancer Ther; 2009 Nov 01; 8(11):2992-3000. PubMed ID: 19887545
    [Abstract] [Full Text] [Related]

  • 3. Wee1 inhibition can suppress tumor proliferation and sensitize p53 mutant colonic cancer cells to the anticancer effect of irinotecan.
    Yin Y, Shen Q, Tao R, Chang W, Li R, Xie G, Liu W, Zhang P, Tao K.
    Mol Med Rep; 2018 Feb 01; 17(2):3344-3349. PubMed ID: 29257266
    [Abstract] [Full Text] [Related]

  • 4. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.
    Rajeshkumar NV, De Oliveira E, Ottenhof N, Watters J, Brooks D, Demuth T, Shumway SD, Mizuarai S, Hirai H, Maitra A, Hidalgo M.
    Clin Cancer Res; 2011 May 01; 17(9):2799-806. PubMed ID: 21389100
    [Abstract] [Full Text] [Related]

  • 5. Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitors.
    Li Y, Saini P, Sriraman A, Dobbelstein M.
    Oncotarget; 2015 Oct 20; 6(32):32339-52. PubMed ID: 26431163
    [Abstract] [Full Text] [Related]

  • 6. Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas.
    Kreahling JM, Foroutan P, Reed D, Martinez G, Razabdouski T, Bui MM, Raghavan M, Letson D, Gillies RJ, Altiok S.
    PLoS One; 2013 Oct 20; 8(3):e57523. PubMed ID: 23520471
    [Abstract] [Full Text] [Related]

  • 7. Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer.
    Wang G, Niu X, Zhang W, Caldwell JT, Edwards H, Chen W, Taub JW, Zhao L, Ge Y.
    Cancer Lett; 2015 Jan 28; 356(2 Pt B):656-68. PubMed ID: 25458954
    [Abstract] [Full Text] [Related]

  • 8. Targeting the checkpoint kinase WEE1: selective sensitization of cancer cells to DNA-damaging drugs.
    Indovina P, Giordano A.
    Cancer Biol Ther; 2010 Apr 01; 9(7):523-5. PubMed ID: 20150761
    [No Abstract] [Full Text] [Related]

  • 9. Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor.
    Mizuarai S, Yamanaka K, Itadani H, Arai T, Nishibata T, Hirai H, Kotani H.
    Mol Cancer; 2009 Jun 08; 8():34. PubMed ID: 19500427
    [Abstract] [Full Text] [Related]

  • 10. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.
    Bridges KA, Hirai H, Buser CA, Brooks C, Liu H, Buchholz TA, Molkentine JM, Mason KA, Meyn RE.
    Clin Cancer Res; 2011 Sep 01; 17(17):5638-48. PubMed ID: 21799033
    [Abstract] [Full Text] [Related]

  • 11. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.
    Guertin AD, Li J, Liu Y, Hurd MS, Schuller AG, Long B, Hirsch HA, Feldman I, Benita Y, Toniatti C, Zawel L, Fawell SE, Gilliland DG, Shumway SD.
    Mol Cancer Ther; 2013 Aug 01; 12(8):1442-52. PubMed ID: 23699655
    [Abstract] [Full Text] [Related]

  • 12. MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells.
    Kreahling JM, Gemmer JY, Reed D, Letson D, Bui M, Altiok S.
    Mol Cancer Ther; 2012 Jan 01; 11(1):174-82. PubMed ID: 22084170
    [Abstract] [Full Text] [Related]

  • 13. Cytokinetic effects of Wee1 disruption in pancreatic cancer.
    Chang Q, Chandrashekhar M, Ketela T, Fedyshyn Y, Moffat J, Hedley D.
    Cell Cycle; 2016 Jan 01; 15(4):593-604. PubMed ID: 26890070
    [Abstract] [Full Text] [Related]

  • 14. Abrogating G₂/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma.
    Indovina P, Marcelli E, Di Marzo D, Casini N, Forte IM, Giorgi F, Alfano L, Pentimalli F, Giordano A.
    Cancer Biol Ther; 2014 Apr 01; 15(4):380-8. PubMed ID: 24365782
    [Abstract] [Full Text] [Related]

  • 15. Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence.
    Osman AA, Monroe MM, Ortega Alves MV, Patel AA, Katsonis P, Fitzgerald AL, Neskey DM, Frederick MJ, Woo SH, Caulin C, Hsu TK, McDonald TO, Kimmel M, Meyn RE, Lichtarge O, Myers JN.
    Mol Cancer Ther; 2015 Feb 01; 14(2):608-19. PubMed ID: 25504633
    [Abstract] [Full Text] [Related]

  • 16. Pharmacological targeting the ATR-CHK1-WEE1 axis involves balancing cell growth stimulation and apoptosis.
    Mak JP, Man WY, Ma HT, Poon RY.
    Oncotarget; 2014 Nov 15; 5(21):10546-57. PubMed ID: 25301733
    [Abstract] [Full Text] [Related]

  • 17. Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair.
    Kausar T, Schreiber JS, Karnak D, Parsels LA, Parsels JD, Davis MA, Zhao L, Maybaum J, Lawrence TS, Morgan MA.
    Neoplasia; 2015 Oct 15; 17(10):757-66. PubMed ID: 26585231
    [Abstract] [Full Text] [Related]

  • 18. Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents.
    Leijen S, Beijnen JH, Schellens JH.
    Curr Clin Pharmacol; 2010 Aug 15; 5(3):186-91. PubMed ID: 20406171
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.
    Jhuraney A, Woods NT, Wright G, Rix L, Kinose F, Kroeger JL, Remily-Wood E, Cress WD, Koomen JM, Brantley SG, Gray JE, Haura EB, Rix U, Monteiro AN.
    Mol Cancer Ther; 2016 Jul 15; 15(7):1669-81. PubMed ID: 27196765
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.